Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 1
2003 1
2004 2
2005 6
2006 4
2007 9
2008 11
2009 13
2010 13
2011 33
2012 35
2013 37
2014 42
2015 54
2016 50
2017 56
2018 45
2019 36
2020 49
2021 46
2022 47
2023 55
2024 45
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

581 results

Results by year

Filters applied: . Clear all
Page 1
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Taylor PC, et al. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345. N Engl J Med. 2017. PMID: 28199814 Free article. Clinical Trial.
BACKGROUND: Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with rheumatoid arthritis. METHODS: We conducted a 52-week, phase 3, double-blind, placebo- and active-controlled trial in …
BACKGROUND: Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with …
2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures.
England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, O'Dell JR, Ranganath VK, Limanni A, Suter LG, Michaud K. England BR, et al. Arthritis Care Res (Hoboken). 2019 Dec;71(12):1540-1555. doi: 10.1002/acr.24042. Epub 2019 Nov 11. Arthritis Care Res (Hoboken). 2019. PMID: 31709779 Free PMC article.
OBJECTIVE: To provide updated American College of Rheumatology (ACR) recommendations on rheumatoid arthritis (RA) disease activity measurements to facilitate a treat-to-target approach in routine clinical care. ...Following a modified Delphi process, 1 …
OBJECTIVE: To provide updated American College of Rheumatology (ACR) recommendations on rheumatoid arthritis (RA) disease
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS. Genovese MC, et al. N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247. N Engl J Med. 2016. PMID: 27028914 Free article. Clinical Trial.
BACKGROUND: In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biologic disease-modifying antirheumatic drugs (DM …
BACKGROUND: In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with …
Application of disease activity index in rheumatoid arthritis management in Korea.
Choi SR, Cho SK, Sung YK. Choi SR, et al. J Rheum Dis. 2024 Oct 1;31(4):193-199. doi: 10.4078/jrd.2024.0077. Epub 2024 Aug 2. J Rheum Dis. 2024. PMID: 39355548 Free PMC article. Review.
Effective management of rheumatoid arthritis (RA) necessitates the accurate measurement of disease activity using a treat-to-target strategy established as a cornerstone approach. Disease activity assessment tools such as the Disease
Effective management of rheumatoid arthritis (RA) necessitates the accurate measurement of disease activity usin …
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators. van der Heijde D, et al. Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24. Arthritis Rheumatol. 2019. PMID: 30666826 Free PMC article. Clinical Trial.
OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). The phase III, 24-month, placebo-controlled Oral Rheumatoid Arthritis (ORAL) Scan trial was undertaken to evaluate the efficacy, including inhibition of str …
OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). The phase III, 24-month, place …
Simplified composite disease activity measures in rheumatoid arthritis: should they be used in standard care?
Bentley MJ, Reed GW. Bentley MJ, et al. Clin Exp Rheumatol. 2008 Mar-Apr;26(2):358-66. Clin Exp Rheumatol. 2008. PMID: 18565264 Review.
OBJECTIVE: To examine the validity, reliability, and predictive value of two recently developed composite disease activity measures, the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index
OBJECTIVE: To examine the validity, reliability, and predictive value of two recently developed composite disease activity mea …
Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial.
Buttgereit F, Aelion J, Rojkovich B, Zubrzycka-Sienkiewicz A, Chen S, Yang Y, Arikan D, D'Cunha R, Pang Y, Kupper H, Radstake T, Amital H. Buttgereit F, et al. Arthritis Rheumatol. 2023 Jun;75(6):879-889. doi: 10.1002/art.42415. Epub 2023 Apr 2. Arthritis Rheumatol. 2023. PMID: 36512671 Clinical Trial.
OBJECTIVE: To assess the efficacy and safety of ABBV-3373, a novel antibody-drug conjugate (ADC) composed of the anti-tumor necrosis factor (anti-TNF) monoclonal antibody adalimumab linked to a glucocorticoid receptor modulator (GRM), compared to adalimumab, in patients with r
OBJECTIVE: To assess the efficacy and safety of ABBV-3373, a novel antibody-drug conjugate (ADC) composed of the anti-tumor necrosis factor …
The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.
Aletaha D, Smolen J. Aletaha D, et al. Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S100-8. Clin Exp Rheumatol. 2005. PMID: 16273793 Review.
Composite indices or pooled indices are useful tools for the evaluation of disease activity in patients with rheumatoid arthritis (RA). They allow the integration of various aspects of the disease into a single numerical value, and may therefore …
Composite indices or pooled indices are useful tools for the evaluation of disease activity in patients with rheumatoid
Performance of the Rheumatoid Arthritis Disease Activity Index in the Assessment of Disease Activity in Rheumatoid Arthritis-Findings From the REAL Study.
Ramon Haddad PA, Vargas-Santos AB, Silva Freire Coutinho E, Rocha Pereira L, Henrique da Mota LM, Pires de Albuquerque C, Brandão de Resende Guimarães MF, Louzada-Júnior P, Rossi Bonfiglioli K, de Carvalho Sacilotto N, Radominski SC, Aliel Vigano Pugliesi A, Lobato da Cunha Sauma MF, Alves Pereira I, Viegas Brenol C, da Rocha Castelar-Pinheiro G. Ramon Haddad PA, et al. J Clin Rheumatol. 2022 Jun 1;28(4):206-211. doi: 10.1097/RHU.0000000000001834. Epub 2022 Mar 22. J Clin Rheumatol. 2022. PMID: 35319537
BACKGROUND/OBJECTIVE: Although telemedicine use has been under discussion for decades, this topic has gained unprecedented importance during the COVID-19 pandemic. The Rheumatoid Arthritis Disease Activity Index (RADAI) is a user-friendly tool, …
BACKGROUND/OBJECTIVE: Although telemedicine use has been under discussion for decades, this topic has gained unprecedented importance during …
Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI.
Gaujoux-Viala C, Mouterde G, Baillet A, Claudepierre P, Fautrel B, Le Loët X, Maillefert JF. Gaujoux-Viala C, et al. Joint Bone Spine. 2012 Mar;79(2):149-55. doi: 10.1016/j.jbspin.2011.04.008. Epub 2011 Jun 15. Joint Bone Spine. 2012. PMID: 21680221 Review.
OBJECTIVES: To evaluate and compare four composite indices for assessing the activity of rheumatoid arthritis (RA). METHODS: We conducted a systematic literature review by searching Medline via PubMed and Embase and Cochrane databases for articles published u …
OBJECTIVES: To evaluate and compare four composite indices for assessing the activity of rheumatoid arthritis (RA). MET …
581 results